生命科学资讯

FDA to end 9-month advisory committee drought with April review of AstraZeneca’s oral SERD, Truqap

Lonza sells capsule and health ingredients unit for $2.2B

Lonza sells capsule and health ingredients unit to UK's Lone Star for $2.2B - Endpoints News

Genomics, multiomics, and spatial biology at AGBT 2026 - C&EN

Agilent Technologies, Inc. (A) Price Target Cut to $155 at Baird - Finviz

Lonza Seals CHF 2.3 Billion CHI Sale to Complete Shift to Pure-Play CDMO - TipRanks

Lonza to sell capsule and health ingredients business to Lone Star for $3.0 billion - Reuters

Servier to build cancer drug pipeline with $2.5B purchase of Day One

Roche, Zealand shares fall on ‘undifferentiated’ obesity drug results

Lonza Completes its Transformation to a Pure-Play CDMO with Agreement to Divest Capsules & Health Ingredients - TradingView

Cas and effect: Merck’s phase III ripples HIF-2α space

Money raised by biopharma

Biopharma money raised: Jan. 1-March 5, 2026

BioWorld and Nasdaq stock indices

FDA issues speedy approval to J&J’s Tecvayli-Darzalex combo

Biopharma money raised by month in 2026 (US$M)

Thermo Fisher Opens Bay Area Cryo-EM Drug Discovery Center - Contract Pharma

Beam rejigs deal to retain base editing technology amid partner's dissolution

Chutes & Ladders—Bavarian Nordic CEO exits on heels of failed takeover

Servier to widen rare cancer offerings with $2.5B buyout of Day One and glioma drug Ojemda